Log in to save to my catalogue

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorect...

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorect...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10803799

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

About this item

Full title

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

Publisher

London: Nature Publishing Group UK

Journal title

British journal of cancer, 2024-02, Vol.130 (2), p.233-241

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Background
FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria.
Methods
The AIO “CHARTA” trial randomised mCRC patients into clinical Group 1 (potentially resectable)...

Alternative Titles

Full title

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10803799

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10803799

Other Identifiers

ISSN

0007-0920,1532-1827

E-ISSN

1532-1827

DOI

10.1038/s41416-023-02496-4

How to access this item